510 Baseline characteristics, hemodynamic, clinical and biochemical response to candesartan in a prospective, multicenter pharmacogenomic study of heart failure patients already receiving an ace inhibitor

Simon de Denus(Montreal Heart Institute), M. White, Anique Ducharme(Montreal Heart Institute), Marie‐Pierre Dubé(Montreal Heart Institute), Eileen O’Meara(Montreal Heart Institute), Normand Racine(Montreal Heart Institute), Jean‐Claude Lavoie(Centre Hospitalier Universitaire Sainte-Justine), Jean‐Claude Tardif(Montreal Heart Institute), Jacques Turgeon(Unknown), M.S. Phillps, Jean L. Rouleau(Montreal Heart Institute), Marie‐Claude Guertin
Canadian Journal of Cardiology
September 1, 2011
10.1016/j.cjca.2011.07.428
Cited by 0

Related Papers

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
|New England Journal of Medicine|2018|3.2k
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
|New England Journal of Medicine|2015|2.3k
Effect of Very High-Intensity Statin Therapy on Regression of Coronary Atherosclerosis
|JAMA|2006|2k
Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
|New England Journal of Medicine|2012|2k